This post was originally published on this site France’s OSE Immunotherapeutics and Léon Bérard Cancer Center have established a research collaboration to use analysis based on artificial intelligence (AI) to identify new targets for cancer immunotherapies. Under the collaboration, researchers will analyze tumor biopsies and patient data to identify the molecular players underlying resistance to PD-1/PD-L1…
This post was originally published on this site The Prostate Cancer Foundation (PCF) has announced the winners of the Scholar-in-Training Awards — research grants to support young scientists who presented outstanding data in the field of prostate cancer. Since 1986, more than 4,580 Scholar-in-Training Awards, encompassing 55 research foundations, corporations, and other organizations dedicated to…
This post was originally published on this site A recent OncLive State of the Science Summit focused on new therapies and other issues in ovarian cancer and soft tissue sarcoma. The March 26 event in New York was chaired by Mario M. Leitao Jr., MD, fellowship director of gynecology service and director of the minimal…
This post was originally published on this site New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in patients with relapsed or refractory multiple myeloma. The results — covering 14 additional months of follow-up — again show 60% of these advanced…
This post was originally published on this site A preliminary study in mice suggests that when a person eats, and not what a person eats, may decrease the risk of breast tumors in obese women. Researchers at the University of California San Diego investigated whether time-restricted feeding (TRF) — eating all meals and snacks within…
This post was originally published on this site To celebrate ovarian cancer survivors while raising funds for research and patient programs, the Be the Difference Foundation will present its signature “Wheel to Survive” event May 19 in Boulder, Colorado. The indoor cycling fundraiser will be from 9 a.m. to noon at DEFINE Body & Mind…
This post was originally published on this site OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the Institute for Myeloma and Bone Cancer Research. The first patent family includes the patent “Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic…
This post was originally published on this site A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, “Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in…
This post was originally published on this site A combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor size in four of 10 patients with aggressive neuroendocrine carcinoma, according to early results of a Phase 2 trial. The research was described in the presentation, “A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1…
This post was originally published on this site First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of a clinical trial show. The study, “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer,” was…
